**Kidney Club Conference**

December 11, 2024

**Purpose**

1 hour educational session presenting UCI faculty overview of late-breaking trials.

**Target Audience**

Specialties – Medicine, Nephrology, Hypertension & Kidney Transplantation

Professions – Physician, Non-Physician, Medical Student, Nurse, Nurse Practitioner, Other, Resident Physician

**Activity Objectives**

1 Analyze current guidelines and develop a strategy to apply in the overall care of patients with CKD, kidney transplants, hypertension, fluid, electrolyte and acid base disorders

2 Critically review and analyze the care of patients undergoing renal replacement therapy using national guidelines and best practices.

3 Critically analyze data from clinical research findings or updated care guidelines and apply it to the care of patients.

**Accreditation Statement**

The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.



ABIM
CME
MOC
Accredited

CME for
ABPath CC

Part 2
MOC
The American Board of Pediatrics

**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Steven Vasquez | Activity Administrator | Nothing to disclose - 10/28/2024 |
| Stefaney Mendoza, BA | Activity Administrator | Nothing to disclose - 03/07/2024 |
| Uttam G Reddy, MD | Faculty | Nothing to disclose - 05/07/2024 |
| John Sy, MD | Co-Director | Nothing to disclose - 10/31/2024 |
| Wei Ling Lau, MD | Course Director, Faculty | Nothing to disclose - 11/11/2024 |
| Ekamol Tantisattamo, MD, MPH, FACP | Co-Director | Nothing to disclose - 05/20/2024 |
| Ramy Hanna, MD | Faculty | Speakers Bureau-Alexion Pharmaceuticals|Consulting Fee-Novartis Corporation Pharmaceuticals|Honoraria-Otsuka America Pharmaceutical, Inc. (Relationship has ended)|Speakers Bureau-AstraZeneca (Any division)|Speakers Bureau-Aurinia|Honoraria-GSK (Relationship has ended)|Speakers Bureau-Calliditas|Independent Contractor (included contracted research)-Roche (Any division)|Independent Contractor (included contracted research)-Apellis|Independent Contractor (included contracted research)-Remegen - 03/13/2024 |

**Agenda**

**[INSERT AGENDA HERE MANUALLY]**

**Acknowledgement of Commercial Support**

No commercial support has been received for this activity.